187 related articles for article (PubMed ID: 22596214)
1. Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis.
Kayakabe K; Kuroiwa T; Sakurai N; Ikeuchi H; Kadiombo AT; Sakairi T; Kaneko Y; Maeshima A; Hiromura K; Nojima Y
Rheumatology (Oxford); 2012 Sep; 51(9):1639-43. PubMed ID: 22596214
[TBL] [Abstract][Full Text] [Related]
2. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents.
Popa C; Barrera P; Joosten LA; van Riel PL; Kullberg BJ; van der Meer JW; Netea MG
Eur Cytokine Netw; 2009 Jun; 20(2):88-93. PubMed ID: 19541595
[TBL] [Abstract][Full Text] [Related]
3. Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy.
Popa C; Netea MG; Barrera P; Radstake TR; van Riel PL; Kullberg BJ; Van der Meer JW
Cytokine; 2005 Apr; 30(2):72-7. PubMed ID: 15804598
[TBL] [Abstract][Full Text] [Related]
4. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
9. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
[TBL] [Abstract][Full Text] [Related]
10. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
[TBL] [Abstract][Full Text] [Related]
11. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
12. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
13. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
Söderlin MK; Petersson IF; Geborek P
Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): p38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis.
Aerts NE; Ebo DG; Bridts CH; Stevens WJ; De Clerck LS
Cytokine; 2009 Sep; 47(3):178-84. PubMed ID: 19616965
[TBL] [Abstract][Full Text] [Related]
15. Effects of TNF inhibitor on innate inflammatory and Th17 cytokines in stimulated whole blood from rheumatoid arthritis patients.
Zivojinovic S; Pejnovic N; Sefik-Bukilica M; Kovacevic L; Soldatovic I; Bugarski D; Mojsilovic S; Damjanov N
Inflammopharmacology; 2012 Dec; 20(6):323-30. PubMed ID: 22733231
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
[TBL] [Abstract][Full Text] [Related]
17. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
18. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
[TBL] [Abstract][Full Text] [Related]
19. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy.
Wright HL; Bucknall RC; Moots RJ; Edwards SW
Rheumatology (Oxford); 2012 Mar; 51(3):451-9. PubMed ID: 22179732
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
